Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

NCT ID: NCT01182194

Last Updated: 2010-12-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30
• Study Completion Date: 2006-08-31

Brief Summary

This study was designed to compare the relative bioavailability (rate and extent of absorption) of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets with that of YAZ® Tablets (by Berlex, Inc.) following a single, oral dose (2 x 3 mg/0.02 mg tablet) in healthy, adult subjects administered under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria Statistical Methods: FDA Bioequivalence Statistical Methods

Conditions

Healthy

Keywords

Bioequivalence; Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

Investigational Test Product

Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg

Group Type: EXPERIMENTAL

Drospirenone/Ethinyl Estradiol (Gianvi®)

Intervention Type: DRUG

3 mg/0.02 mg Tablets

Reference Listed Drug

YAZ® Tablets, 3 mg/0.02 mg

Group Type: ACTIVE_COMPARATOR

YAZ®

Intervention Type: DRUG

3 mg/0.02 mg Tablets

Interventions

Drospirenone/Ethinyl Estradiol (Gianvi®)

3 mg/0.02 mg Tablets

Intervention Type: DRUG

YAZ®

3 mg/0.02 mg Tablets

Intervention Type: DRUG

Other Intervention Names

Gianvi®; Drospirenone/Ethinyl Estradiol (generic name)

Eligibility Criteria

Inclusion Criteria

• Subjects who were informed of the nature of the study and agreed to read, review, and sign the informed consent document prior to Period I dosing.
• Subjects who completed the screening process within 28 days prior to Period I dosing.
• Subjects who were healthy adult menstruating women 18 to 35 years of age, inclusive, at the time of dosing.
• Subjects with a body mass index (BMI) between 19 and 30 kg/m2, inclusive, and weigh at least 110 pounds.
• Subjects who were healthy as documented by the medical history, physical examination, vital sign assessments, and by general observations. The physical examination also included a gynecological exam. If the subject had completed an acceptable Pap smear and gynecological exam in the previous 12 months (prior to study Day 1) and documentation of acceptable results were provided, both were deferred. Any abnormalities/deviations from the normal range which were considered clinically relevant by the study physician and investigator were evaluated for individual cases, documented in study files, and agreed upon by the study physician and investigator prior to enrolling a volunteer in this study and for continued enrollment.
• Female subjects who practiced an acceptable non-hormonal method of birth control as judged by the investigator(s) at least 14 days prior to Period I dosing and throughout the study and until 14 days after the Period II dosing. The acceptable non-hormonal birth control methods included: double barriers, non-hormonal releasing intrauterine device in place for at least 30 days prior to dosing, abstinence throughout the duration of the study, or surgically sterile for at least 6 months prior to Period I dosing.

Exclusion Criteria

• Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
• Volunteers who report taking any oral contraceptives including estrogen and progestin combined pills and progestin only pills or patch within 28 days prior to Period I dosing, or using injectable contraceptives within 6 months of Period I dosing.
• Volunteers who have ever had progestational hormone implants.
• Volunteers who reported any presence of history of a clinically significant disorder involving the cardiovascular, respiratory, renal, liver, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric or epilepsy disease as determined by the clinical investigator(s).
• Volunteers who reported any presence or history of migraines or severe headaches.
• Volunteers who had a systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 45 or over 90 mmHg were excluded from the study.
• Volunteers who had a history of thrombotic disorders or have ever had cerebrovascular accident or transient ischemic attacks.
• Volunteer with a history of breast cancer or undiagnosed breast nodules, active malignancies, or undiagnosed vaginal bleeding.
• Volunteers having other conditions that may be aggravated by fluid retention as determined by the principal investigator.
• Volunteers who has a history of jaundice with previous use of oral contraceptives or any other kinds of hormonal contraceptives.
• Volunteers whose clinical laboratory test values were outside the accepted reference range and when confirmed on re-examination were deemed to be clinically significant.
• Volunteers who demonstrated a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
• Volunteers who reported a history of allergic response(s) to drospirenone/ethinyl estradiol, progestin/estrogens, or related drugs.
• Volunteers who reported the use of any systemic prescription medication in the 14 days prior to Period I dosing (with the exception of hormonal contraceptives).
• Volunteers who reported the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
• Volunteers who reported a history of clinically significant allergies including drug allergies.
• Volunteers who reported a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
• Volunteers who reported a history of drug or alcohol addiction or abuse within the past year.
• Volunteers who demonstrated a positive drug abuse screen for the study prior to Period I dosing.
• Volunteers who used tobacco products in the past 6 months.
• Volunteers who reported donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects were advised not to donate blood for 4 weeks after completing the study.
• Volunteers who reported donating plasma within 30 days prior to Period I dosing. All subjects were advised not to donate plasma for 4 weeks after completing the study.
• Volunteers who demonstrated a positive pregnancy screen.
• Volunteers who are currently breastfeeding.
• Volunteers who had used within the 3 months preceding Period I dosing and vaginally administered estrogen or progestin containing products.
• Any volunteer who engaged in unprotected sexual intercourse during the time interval starting at 14 days prior to the first period and until 14 days after the Period II dosing.
• Volunteers who had a hysterectomy or oophorectomy.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

Anthony R Godfrey, Pharm.D.

Role: PRINCIPAL_INVESTIGATOR

PRACS Institute, Ltd.

Locations

PRACS Institute, Ltd.

Fargo, North Dakota, United States

Countries

United States

Other Identifiers

R06-0631

Identifier Type: -

Identifier Source: org_study_id